文献速递眼底病与葡萄膜炎

他克莫司用于非感染性中间型、后型或全葡萄膜炎患者的免疫抑制治疗

TACROLIMUS FOR IMMUNOSUPPRESSION IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE, POSTERIOR, OR PANUVEITIDES.
PubMed 文献 · Retina · 2023-01-01

这项回顾性队列研究纳入32例非感染性中间型、后型或全葡萄膜炎患者,在单药免疫抑制不足以实现成功激素节约时加用他克莫司作为第二种免疫抑制药。他克莫司起始时65.6%患者有活动性葡萄膜炎,中位达不活动时间1.5个月,中位达成功激素节约时间3.9个月,6个月随访时75%患者达到成功激素节约。5例因副作用停药,副作用停药后均可逆。

要点

  • 他克莫司作为第二种免疫抑制药,中位3.9个月达到成功激素节约。
  • 6个月随访时75%患者达到成功激素节约,定义泼尼松≤7.5 mg/天且葡萄膜炎不活动。
  • 5例因副作用停药,3例震颤、2例高血糖,停药后副作用均可逆。

核心结论

  • 他克莫司作为两种免疫抑制药方案中的第二种药物似乎有效,适用于单药不能实现成功激素节约时。
  • 停用他克莫司后副作用均可逆。

研究设计与样本

  • 回顾性队列研究,设置于两家学术医疗中心的三级医疗葡萄膜炎 practice。
  • 纳入32例非感染性中间型、后型或全葡萄膜炎患者,单药免疫抑制不足以实现成功激素节约。
  • 干预为他克莫司作为第二种免疫抑制药加入。

主要发现

  • 他克莫司起始时65.6%患者有活动性葡萄膜炎。
  • 中位达不活动葡萄膜炎时间为1.5个月(95%CI 1.2, 4.08)。
  • 中位达成功激素节约时间为3.9个月(95%CI 1.41, 6.67)。
  • 6个月随访时75%患者达到成功激素节约。
  • 5例因副作用停用他克莫司,3例震颤、2例高血糖,停药后副作用均可逆。

关键数值与推荐

  • 成功激素节约定义为泼尼松≤7.5 mg/天时葡萄膜炎不活动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effectiveness of tacrolimus in patients with noninfectious intermediate, posterior, or panuveitis needing a two-immunosuppressive-agent regimen. METHODS: Design: Retrospective cohort study. Setting: Two tertiary-care uveitis practices at academic medical centers. Patient population: Thirty-two patients with noninfectious intermediate, posterior, or panuveitides in whom single-agent immunosuppression was inadequate to effect successful corticosteroid sparing. Intervention: tacrolimus, added as the second immunosuppressive agent. Main outcome measure: successful corticosteroid sparing, defined as inactive uveitis at a dose of prednisone ≤7.5 mg/day. RESULTS: Active uveitis was present in 65.6% of patients at initiation of tacrolimus, and the median time to inactive uveitis was 1.5 months (95% confidence interval 1.2, 4.08). The median time to successful corticosteroid sparing was 3.9 months (95% confidence interval 1.41, 6.67), and by 6 months of follow-up successful corticosteroid sparing was achieved in 75% of patients. Tacrolimus was discontinued for side effects in five patients, three for tremor, and two for hyperglycemia. All side effects were reversible with tacrolimus discontinuation. CONCLUSION: Tacrolimus seems to have efficacy as a second immunosuppressive agent in two-immunosuppressive drug regimens, when a single agent does not permit successful corticosteroid sparing. Side effects were reversible with tacrolimus discontinuation.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Jabs DA, Thorne JE, Wilkins CS, et al. TACROLIMUS FOR IMMUNOSUPPRESSION IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE, POSTERIOR, OR PANUVEITIDES. Retina. 2023. PMID: 37184495. doi:10.1097/IAE.0000000000003836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。